bacitracin zinc + neomycin sulfate + lidocaine hydrochloride + polymyxin b

A topical **small-molecule combination drug** comprising bacitracin zinc, neomycin sulfate, polymyxin b, and lidocaine hydrochloride. The antibiotic components provide broad first-aid anti-infective coverage through complementary mechanisms: bacitracin inhibits bacterial cell wall synthesis, neomycin inhibits bacterial protein synthesis by binding the bacterial ribosome, and polymyxin b disrupts bacterial cell membrane integrity; lidocaine hydrochloride adds local anesthetic activity by blocking voltage-gated sodium channels. The product is marketed in **cream** and **ointment** formulations for minor cuts, scrapes, and burns, and the provided context also links the lidocaine-containing topical concept to use in **painful urethritis**. This is an OTC multi-ingredient pharmaceutical product rather than a novel proprietary biotech asset, with public-source mentions including branded listings such as RECELLTIS and manufacturer-linked branded products such as Biotic-Plus.

Brand names

RECELLTISBiotic-Plus

Other names

bacitracin zinc + neomycin sulfate + lidocaine hydrochloride + polymyxin bbacitracin zinc + neomycin sulfate + lidocaine hydrochloride + polymyxin b sulfatebacitracin zinc + neomycin sulfate + lidocaine hydrochloride + polymyxin b sulfate ointmentbacitracin zinc + neomycin sulfate + lidocaine hydrochloride + polymyxin b sulfate cream